MicroPort MedBot Forecasts First-Ever Profit for H1 2026

Key Facts

In a move reflecting a major fundamental shift in the health-tech sector, MicroPort MedBot has announced expectations to achieve its first-ever profit during the first half of 2026. According to reports, the company forecasts a net profit between 28 million and 40 million yuan, reversing years of consecutive financial losses. This turnaround is primarily driven by booming exports and strong international demand for its advanced medical robotic systems.

The projected profitability is supported by a massive revenue surge of 200% to 230% compared to the first half of the previous year, alongside a gross margin improvement of over 15 percentage points. Per market data, the Toumai laparoscopic surgical robots have emerged as a flagship product, achieving commercial installations in 60 global markets, including new entries such as Saudi Arabia and South Korea. A 30% reduction in R&D spending also contributed to the improved bottom line.

While specific price data for the instrument was unavailable at the close of July 24, 2026, investors are closely monitoring the sustainability of this growth amid broader economic conditions in China. Recent data showed China's Loan Prime Rate remained steady at 3% as of July 20, 2026, providing a stable financing environment for regional growth-stage technology companies in the near term.